Cargando…

Angiotensin II Type 1 Receptor Blocker, Fimasartan, Reduces Vascular Smooth Muscle Cell Senescence by Inhibiting the CYR61 Signaling Pathway

BACKGROUND AND OBJECTIVES: Angiotensin II (Ang II) has been suggested to accelerate vascular senescence, however the molecular mechanism(s) remain unknown. METHODS: We cultured human coronary artery smooth muscle cells (hCSMCs) and treated Ang II and/or fimasartan. Or we transfected adenoviral vecto...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kim, Inho, Park, Chan Soon, Lee, Hae-Young
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Korean Society of Cardiology 2019
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6597448/ https://www.ncbi.nlm.nih.gov/pubmed/31074217 http://dx.doi.org/10.4070/kcj.2018.0379

Ejemplares similares

Cyr61 Mediates Angiotensin II-Induced Podocyte Apoptosis via the Upregulation of TXNIP
por: Ma, Jingxue, et al.
Publicado: (2023)

Cysteine-rich 61 (Cyr61) upregulated in pulmonary arterial hypertension promotes the proliferation of pulmonary artery smooth muscle cells
por: Gao, Lan, et al.
Publicado: (2017)

Placental transfer and mammary excretion of a novel angiotensin receptor blocker fimasartan in rats
por: Kim, Tae Hwan, et al.
Publicado: (2016)

Fimasartan, an angiotensin II receptor antagonist, ameliorates an in vivo zebrafish model of heart failure
por: Quan, Hailian, et al.
Publicado: (2020)

Cardioprotective Effect of Fimasartan, a New Angiotensin Receptor Blocker, in a Porcine Model of Acute Myocardial Infarction
por: Sim, Doo Sun, et al.
Publicado: (2015)

Clinic and Home Blood Pressure Lowering Effect of an Angiotensin Receptor Blocker, Fimasartan, in Postmenopausal Women with Hypertension
por: Kim, Song-Yi, et al.
Publicado: (2016)

Fimasartan-induced liver injury in a patient with no adverse reactions on other types of angiotensin II receptor blockers: A case report
por: Park, Dae Hwa, et al.
Publicado: (2017)

The Roles of CCN1/CYR61 in Pulmonary Diseases
por: Zhu, Yin, et al.
Publicado: (2020)

Comparison Between Fimasartan Versus Other Angiotensin Receptor Blockers in Patients With Heart Failure After Acute Myocardial Infarction
por: Kim, Jihoon, et al.
Publicado: (2023)

CYR61 as a potential biomarker for the preoperative identification of muscle-invasive bladder cancers
por: Chen, Huang, et al.
Publicado: (2021)

The Matricellular Protein CCN1/CYR61 Induces Fibroblast Senescence and Restricts Fibrosis in Cutaneous Wound Healing
por: Jun, Joon-Il, et al.
Publicado: (2010)

INCREASED VASCULARITY AND SPONTANEOUS METASTASIS OF BREAST CANCER BY HEDGEHOG SIGNALING MEDIATED UPREGULATION OF CYR61
por: Harris, Lillianne G., et al.
Publicado: (2011)

Cyr61 Expression is associated with prognosis in patients with colorectal cancer
por: Jeong, Dongjun, et al.
Publicado: (2014)

Cyr61: a potential therapeutic target for prostate cancer
por: Lin, Chang-Ming, et al.
Publicado: (2014)

STROBE: The correlation of Cyr61, CTGF, and VEGF with polymyositis/dermatomyositis
por: Chai, Ke-Xia, et al.
Publicado: (2018)

Aberrant activation of CYR61 enhancers in colorectal cancer development
por: Xie, Lingzhu, et al.
Publicado: (2019)

Cyr61/CCN1 targets for chemosensitization in pancreatic cancer
por: Banerjee, Snigdha, et al.
Publicado: (2019)

Fimasartan, a Novel Angiotensin-Receptor Blocker, Protects against Renal Inflammation and Fibrosis in Mice with Unilateral Ureteral Obstruction: the Possible Role of Nrf2
por: Kim, Soojeong, et al.
Publicado: (2015)

Functional angiotensin II receptors in cultured vascular smooth muscle cells
Publicado: (1982)

Cysteine-rich 61 (Cyr61): a biomarker reflecting disease activity in rheumatoid arthritis
por: Fan, Yong, et al.
Publicado: (2019)

Identification of the Transcriptional Networks and the Involvement in Angiotensin II-Induced Injury after CRISPR/Cas9-Mediated Knockdown of Cyr61 in HEK293T Cells
por: Wang, Junjie, et al.
Publicado: (2019)

Whey Protein Attenuates Angiotensin II-Primed Premature Senescence of Vascular Smooth Muscle Cells through Upregulation of SIRT1
por: Hwang, Jung Seok, et al.
Publicado: (2017)

Targeting Molecular Mechanism of Vascular Smooth Muscle Senescence Induced by Angiotensin II, A Potential Therapy via Senolytics and Senomorphics
por: Okuno, Keisuke, et al.
Publicado: (2020)

Duck Oil-loaded Nanoemulsion Inhibits Senescence of Angiotensin II-treated Vascular Smooth Muscle Cells by Upregulating SIRT1
por: Kang, Eun Sil, et al.
Publicado: (2020)

Involvement of Cyr61 in growth, migration, and metastasis of prostate cancer cells
por: Sun, Z-J, et al.
Publicado: (2008)

The matrix protein CCN1 (CYR61) induces apoptosis in fibroblasts
por: Todorovicç, Viktor, et al.
Publicado: (2005)

The profile of Cyr61 expression data correlate to the skin inflammation in psoriasis
por: Wu, Pinru, et al.
Publicado: (2016)

Cyr61 Promotes Inflammation of a Gouty Arthritis Model in Rats
por: Zhou, Mi, et al.
Publicado: (2020)

Expression of Cyr61 is associated with clinical course in patients with Crohn’s disease
por: Lee, Su-Mi, et al.
Publicado: (2021)

Angiotensin II-Regulated Autophagy Is Required for Vascular Smooth Muscle Cell Hypertrophy
por: Mondaca-Ruff, David, et al.
Publicado: (2019)

Senescence in Vascular Smooth Muscle Cells and Atherosclerosis
por: Zha, Yiwen, et al.
Publicado: (2022)

Different Effects of Angiotensin II and Angiotensin-(1-7) on Vascular Smooth Muscle Cell Proliferation and Migration
por: Zhang, Feng, et al.
Publicado: (2010)

Angiotensin II Requires Zinc and Downregulation of the Zinc Transporters ZnT3 and ZnT10 to Induce Senescence of Vascular Smooth Muscle Cells
por: Patrushev, Nikolay, et al.
Publicado: (2012)

Angiotensin II, Hypercholesterolemia, and Vascular Smooth Muscle Cells: A Perfect Trio for Vascular Pathology
por: St. Paul, Amanda, et al.
Publicado: (2020)

Efficacy of fimasartan/hydrochlorothiazide combination in hypertensive patients inadequately controlled by fimasartan monotherapy
por: Rhee, Moo-Yong, et al.
Publicado: (2015)

Cyr61 as mediator of Src signaling in triple negative breast cancer cells
por: Sánchez-Bailón, María Pilar, et al.
Publicado: (2015)

Matricellular proteins of the Cyr61/CTGF/NOV (CCN) family and the nervous system
por: Malik, Anna R., et al.
Publicado: (2015)

CYR61 (CCN1) is a metastatic biomarker of gastric cardia adenocarcinoma
por: Wei, Jing, et al.
Publicado: (2016)

Serum CYR61 as a potential biomarker for the diagnosis of esophagogastric junction tumor
por: Chu, Ling-Yu, et al.
Publicado: (2021)

Regulation of angiotensin II actions by enhancers and super-enhancers in vascular smooth muscle cells
por: Das, Sadhan, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_rdnaesa2mk849umgvdvl0h54l1